Navigation Links
Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Date:9/8/2008

CALGARY, Sept. 8 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that that it has started patient enrolment in a Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers. The Principal Investigator is Dr. Monica Mita of the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio.

"We are extremely pleased to open the second disease-directed study with REOLYSIN(R)," said Dr. Mita. "This study represents a promising option for patients with head and neck tumors refractory to standard chemotherapy and we are happy to have the opportunity to offer this option to our patients."

This trial is a 14-patient, single arm, open-label, dose-targeted, non-randomized trial of REOLYSIN(R) given intravenously in combination with a standard dosage of paclitaxel and carboplatin.

Eligible patients include those with advanced or metastatic head and neck cancers that are refractory to standard therapy or for which no curative standard therapy exists. The primary objective of the Phase 2 trial is to measure tumour responses and duration of response, and to describe any evidence of antitumour activity. The secondary objective is to determine the safety and tolerability of REOLYSIN(R) when administered in combination with paclitaxel and carboplatin to patients with advanced or metastatic head and neck cancers.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit '/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. /R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
2. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
3. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
4. Oncolytics Biotech Inc. Announces 2008 Second Quarter Results
5. Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies with REOLYSIN(R)
6. Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
7. Oncolytics Biotech Inc. to Present at BIO 2008 International Convention
8. Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN(R)
9. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
10. Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
11. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at ASGT Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Freeslate, Inc ., the leading provider of ... one of India’s top five pharmaceutical companies, has received ... for high throughput solid form screening. , Lupin, ... range of quality, affordable generic and branded formulations and ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
(Date:1/14/2014)... 2014  3D Communications, a leading provider of strategic communications services to ... events in the United States and ... Cox , JD, is returning to the firm,s Washington, ... 3D after more than two years of service as Associate Commissioner ...
(Date:1/14/2014)... Texas , Jan. 14, 2014 The ... and research medicinal plants and therapeutic derivatives thereof ... health professionals, and researchers about the challenges of ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8
... Fla., Oct. 7 GeneWize Life Sciences ... Bulletin Board: GNLK) announced before a full house of ... targeting the teen market, adding to their current flagship ... The new nutrition and skin-clearing products, aimed ...
... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... Executive Officer of BioMarin, will host a ... 28, at 5:00 p.m. ET to discuss ... Dial-in Number:  866.202.3048International Dial-in Number:  617.213.8843Participant Code: ...
... JOSEPH, Mich., Oct. 7 GeneGo, Inc., a leading ... and chemistry, announced today that they have integrated GenomeQuest,s ... MetaDrug. Using GenomeQuest,s interactive analysis, scientists who ... of interest (hundreds of millions of reads, to thousands ...
Cached Biology Technology:GeneWize Announces New Skin Clearing Product and Teen Nutrition at Annual Convention 2BioMarin to Host Third Quarter 2010 Financial Results Conference Call and Webcast on Thursday, October 28 at 5:00 p.m. ET 2GeneGo Announces Integration With GenomeQuest for Pathway Analysis of Next Generation Sequencing Data 2
(Date:7/9/2014)... to species, selection for traits that are attractive to ... enhances opportunities to mate, the tail of male peacocks ... of California, Riverside have now found that sexual selection ... are linked. Describing the life histories of more than ... researchers found that species with placentas tend to have ...
(Date:7/9/2014)... critically ill children with traumatic injuries have identified ... likely to develop a hospital-acquired infection. The study, ... published online in June in the journal ... that could lead to the clinical implementation of ... or reverse immune system damage following critical illness ...
(Date:7/9/2014)... 100 diseases that can attack soybean crops, why would ... wanted list? University of Illinois scientists cite the earth,s ... needed on the fungus that causes charcoal rot. , ... conditions but Macrophomina phaseolina , the fungus that ... , "As the climate continues to change and we ...
Breaking Biology News(10 mins):Biologists link sexual selection and placenta formation 2Biologists link sexual selection and placenta formation 3Biologists link sexual selection and placenta formation 4Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3Climate change provides good growing conditions for charcoal rot in soybeans 2Climate change provides good growing conditions for charcoal rot in soybeans 3
... EUREKA Chairmanship 2009/2010! The conference, hosted and conceptually designed ... be held on July 6-7, 2009, at Maritim Hotel ... heart of the city, only a few steps away ... the current and future opportunities and challenges for Europe,s ...
... used by millions worldwide to effectively lower blood cholesterol ... Sclerosis (MS) patients treated with high daily dosages. ... Institute (MNI), McGill University, demonstrates that statin therapy in ... nervous system. The findings, published in The American ...
... to model in mice because their symptoms are complex ... when transferred to a mouse. The lack of animal ... By strategically altering a protein-making molecule, a mouse was ... feeling and cause paralysis of the arms and legs ...
Cached Biology News:One size does not fit all 2A new mouse model provides insight into genetic neurological disorders 2
Request Info...
2 ml SmartScan Racks...
... Immunogen: Partially purified ... MA1-710 detects vitamin D receptor (VDR) ... amphibian, and fish tissues. This ... or glucocorticoid receptors. MA1-710 detects ...
... The integration of 2D polyacrylamide gel electrophoresis ... regarded as a core technology platform for ... power for complex samples limited only in ... small and large proteins. Quantitative image based ...
Biology Products: